iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will present updated clinical data, host in-booth clinician presentations and showcase the latest in radiation technology at the American Society for Radiation Oncology (ASTRO) meeting in San Antonio, TX from October 18-21, 2015.

Retroactively implementing ACR’s 2014 LungRADS classification criteria, an academic medical center increased the positive predictive value in a CT lung-screening cohort of more than 1,600 patients by a factor of 2.5—without driving an increase in surgeries following false negatives.

Eli Lilly and Company (NYSE: LLY) and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel T cell-based immuno-oncology therapies.

They sparkle on your jewelry, but researchers in Australia are investigating whether they can make diamonds that also light up on MRI in order to help spot cancers.

Varian Medical Systems received regulatory clearance in the U.S. and Europe for its VitalBeam radiotherapy platform, netting both 510(k) clearance from the FDA and the CE Mark.

CMS is proposing not to offer lenience on its reimbursement constraints around a sodium-fluoride PET agent, NaF-18, which is used in finding metastasized cancer cells in bones.

A new MRI technique being studied at Memorial Sloan Kettering Cancer Center in New York City could cut the time needed to reveal whether a tumor is responding to treatment from a matter of weeks to just a few days.

Cell-based therapies that exploit modified human cells to treat cancer have been a promising area of research, but issues remain. Specifically, the driver-less cells are difficult to target, especially in tissues deep in the body.